Impact of IFNL4-ΔG genotype on sustained virologic response in hepatitis C genotype 1 patients treated with direct-acting antivirals

被引：5
|
作者：
Backus, Lisa I. [1 ]
Shahoumian, Troy A. [1 ]
Belperio, Pamela S. [1 ]
Winters, Mark [2 ]
Prokunina-Olsson, Ludmila [3 ]
O'Brien, Thomas R. [3 ]
Holodniy, Mark [2 ,4 ]
机构：
[1] Populat Hlth Serv, Dept Vet Affairs, Palo Alto, CA 94304 USA
[2] Stanford Univ, Div Infect Dis & Geog Med, Stanford, CA 94305 USA
[3] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA
[4] Off Publ Hlth Surveillance & Res, Dept Vet Affairs, Palo Alto, CA 94304 USA
来源：
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE | 2018年 / 92卷 / 01期
基金：
美国国家卫生研究院;
关键词：
IFNL4; SVR; hepatitis C virus; DAA therapy; Veterans; HCV CLEARANCE; VIRUS; IFNL4; ASSOCIATION; INFECTION; RIBAVIRIN; VARIANTS; THERAPY; IL28B;
D O I：
10.1016/j.diagmicrobio.2018.04.004
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
In direct acting antiviral (DAA)-treated HCV genotype 1, the sustained virologic response rate with the Delta G/Delta G genotype of IFNL4 rs368234815 (86.8%) was significantly lower than with Delta G/TT (95.9%, P = 0.03) or TT/IT (98.6%, P = 0.01). The SVR odds ratio for Delta G/Delta G compared to TT/TT was 0.10 (P = 0.03). IFNL4 genotype might predict DAA-response. Published by Elsevier Inc.
引用
收藏
页码：34 / 36
页数：3
相关论文
共 50 条
  • [21] Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure
    Poordad, Fred
    Pol, Stanislas
    Asatryan, Armen
    Buti, Maria
    Shaw, David
    Hezode, Christophe
    Felizarta, Franco
    Reindollar, Robert W.
    Gordon, Stuart C.
    Pianko, Stephen
    Fried, Michael W.
    Bernstein, David E.
    Gallant, Joel
    Lin, Chih-Wei
    Lei, Yang
    Ng, Teresa I.
    Krishnan, Preethi
    Kopecky-Bromberg, Sarah
    Kort, Jens
    Mensa, Federico J.
    HEPATOLOGY, 2018, 67 (04) : 1253 - 1260
  • [22] Optimism for patients with genotype 4 HCV infection: Clinical trials with direct-acting antivirals finally available
    Asselah, Tarik
    JOURNAL OF HEPATOLOGY, 2015, 62 (05) : 996 - 999
  • [23] Retreatment of patients with treatment failure of direct-acting antivirals: Focus on hepatitis C virus genotype 1b
    Kanda, Tatsuo
    Nirei, Kazushige
    Matsumoto, Naoki
    Higuchi, Teruhisa
    Nakamura, Hitomi
    Yamagami, Hiroaki
    Matsuoka, Shunichi
    Moriyama, Mitsuhiko
    WORLD JOURNAL OF GASTROENTEROLOGY, 2017, 23 (46) : 8120 - 8127
  • [24] The Prevalence of Mixed Hepatitis C Virus Genotype Infection and Its Effect on the Response to Direct-Acting Antivirals Therapy
    Hayashi, Kazuhiko
    Tachi, Kosuke
    Shimizu, Yuko
    Nagano, Kenichi
    Ishizu, Yoji
    Kuzuya, Teiji
    Honda, Takashi
    Ishigami, Masatoshi
    Hirooka, Yoshiki
    Hattori, Masashi
    Goto, Hidemi
    INTERVIROLOGY, 2019, 62 (01) : 23 - 29
  • [25] Sofosbuvir-velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals
    Izumi, Namiki
    Takehara, Tetsuo
    Chayama, Kazuaki
    Yatsuhashi, Hiroshi
    Takaguchi, Koichi
    Ide, Tatsuya
    Kurosaki, Masayuki
    Ueno, Yoshiyuki
    Toyoda, Hidenori
    Kakizaki, Satoru
    Tanaka, Yasuhito
    Kawakami, Yoshiiku
    Enomoto, Hirayuki
    Ikeda, Fusao
    Jiang, Deyuan
    De-Oertel, Shampa
    McNabb, Brian L.
    Camus, Gregory
    Stamm, Luisa M.
    Brainard, Diana M.
    McHutchison, John G.
    Mochida, Satoshi
    Mizokami, Masashi
    HEPATOLOGY INTERNATIONAL, 2018, 12 (04) : 356 - 367
  • [26] Direct-acting antiviral agents in patients with hepatitis C genotype 1-4 infections in a tertiary hospital
    Carlos del Rio-Valencia, Juan
    Asensi-Diez, Rocio
    Villalobos-Torres, Lorenzo
    Munoz Castillo, Isabel
    REVISTA ESPANOLA DE QUIMIOTERAPIA, 2018, 31 (03) : 226 - 236
  • [27] Improvement of patient-reported outcomes in patients achieving sustained virologic response with direct-acting antivirals for hepatitis C virus infection
    Yi, Chih-Hsun
    Bair, Ming -Jong
    Wang, Jen-Hung
    Wong, Ming-Wun
    Liu, Tso-Tsai
    Lei, Wei-Yi
    Liang, Shu-Wei
    Lin, Lin
    Hung, Jui-Sheng
    Huang, Jee-Fu
    Hsu, Yao-Chun
    Chen, Chien -Lin
    JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION, 2022, 55 (04) : 643 - 650
  • [28] Economic evaluation of direct-acting antivirals for the treatment of genotype 3 hepatitis C infection in Singapore
    Wong, Yu-Jun
    Cheen, McVin H. H.
    Hsiang, John C.
    Kumar, Rahul
    Tan, Jessica
    Teo, Eng K.
    Thurairajah, Prem H.
    JGH OPEN, 2019, 3 (03): : 210 - 216
  • [29] High rate of acute kidney injury in patients with chronic kidney disease and hepatitis C virus genotype 4 treated with direct-acting antiviral agents
    Elmowafy, Ahmed Yahia
    El Maghrabi, Hanzada Mohamed
    Mashaly, Mohamed Elsayed
    Eldahshan, Khaled Farouk
    Rostaing, Lionel
    Bakr, Mohamed Adel
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2019, 51 (12) : 2243 - 2254
  • [30] Impact of Substance Use Disorder on the Rate of Sustained Virological Response in Veterans With Chronic Hepatitis C Treated With Direct-Acting Antivirals
    Ottman, Andreina A.
    Townsend, Mary L.
    Hashem, Mohamed G.
    Britt, Rachel B.
    ANNALS OF PHARMACOTHERAPY, 2019, 53 (06) : 581 - 587
12345